尿路性器悪性腫瘍に対するCis-Diamminedichloroplatinum (CDDP)の使用経験

Abstract

前立腺癌3例, 膀胱癌3例, 腎癌5例, 悪性褐色細胞腫1例, 睾丸腫瘍6例の2A以上の遠隔転移を有する進行性悪性腫瘍の18例に対しCDDPを主体とする化学療法を行なった.単独よりも多剤併用時の方が, 効果は優った.前立腺癌3例, 膀胱癌3例, 腎癌5例には効果が認められなかったが, 睾丸腫瘍の6例中4例にPR, 1例にCRが認められた.副作用としては, 悪心, 嘔吐(体重減少), 腎機能障害などが主であった

Eighteen patients with advanced genitourinary carcinoma have been treated with cis-diamminedichloroplatinum (CDDP) since 1978, at our University Hospital. They were 3 patients with prostatic cancer, 3 patients with bladder cancer, 6 patients with testicular tumors, 5 patients with renal cell carcinoma and 1 patient with malignant pheochromocytoma. Four patients with testicular tumors were administrated CDDP, bleomycin (BLM) and vinblastine (VBL). A testicular tumor patient was given CDDP, vincristine and actinomycin-D, a bladder cancer patient was given CDDP, VBL and Pepleomycin as combined chemotherapy. The remaining 12 patients were treated only with CDDP. Five of the 6 patients with testicular tumor and a case of choriocarcinoma of left kidney showed an objective response. As side effects, bone marrow suppression was inevitable when VBL and BLM were given along with CDDP. Renal dysfunction was seen in 5 patients on whom BVP regimen was employed. Various degrees of nausea and vomiting were present in almost all patients during CDDP administration. The combination chemotherapy with CDDP appears to be effective in nonseminomatous testicular tumor. The effectiveness of CDDP against other genitourinary carcinomas may require further investigation.